Probiotic bacillus compositions and methods of use
AssigneeElanco US Inc.
InventorsDharanesh Mahimapura Gangaiah, Arvind Kumar, Shrinivasrao Peerajirao Mane, Dwi Susanti, Alyssa Volland
Life of this patent
Estimating the term…
Abstract
The present invention relates to probiotic compositions and methods for improving animal health and animal production. The probiotic compositions include one, two, three, or more isolated strains of novel Bacillus strains which are capable of colonizing the gastrointestinal tract to improve the health of an animal. The probiotic compositions include a combination of at least one Bacillus amyloliquefaciens strain and a Bacillus subtilis strain.
Claims84
A probiotic composition comprising at least one of:
- a first isolated Bacillus amyloliquefaciens strain, a second isolated Bacillus amyloliquefaciens strain, and a first isolated Bacillus subtilis strain;
- and a carrier suitable for animal administration;
- wherein said composition reduces or inhibits the colonization of an animal by a pathogenic bacterium when an effective amount is administered to an animal, as compared to an animal not administered the composition;
- and
- wherein the first isolated Bacillus amyloliquefaciens strain comprises a nucleic acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:
- 5 or comprises a nucleic acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:
- 261;
- wherein the second Bacillus amyloliquefaciens strain comprises a nucleic acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:
- 10 or 11 or comprises a nucleic acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:
- 262;
- wherein the first Bacillus subtilis strain comprises a nucleic acid sequence having at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity with SEQ ID NO:
- 16.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of preparing a fermentation product comprising the steps of:
- (a) obtaining at least one bacterial strain selected from a first isolated Bacillus amyloliquefaciens strain comprising SEQ ID NO:
- 5 or comprising SEQ ID NO:
- 261 or nucleic acid encoding one or more of SEQ ID NOs:
- 263-276, a second isolated Bacillus amyloliquefaciens strain comprising SEQ ID NO:
- 10 or 11 or comprising SEQ ID NO:262 or nucleic acid encoding one or more of SEQ ID NOs:
- 277-284, and a first isolated Bacillus subtilis strain comprising SEQ ID NO:
- 257 or comprising nucleic acid encoding one or more of SEQ ID NOs:
- 285-305;
- (b) contacting the at least one strain of step (a) with cell growth media;
- (c) incubating a combination of at least one strain of step (a) and cell growth media of step (b) at a temperature of about 37° C. for an incubation time of about 24 hours;
- and
- (d) cooling the combination of step (c);
- wherein the product of step (d) comprises the fermentation product.
(canceled)
A method of delivering a metabolite to the gut of an animal, said method comprising administering to an animal a composition comprising:
- a first isolated Bacillus amyloliquefaciens strain comprising SEQ ID NO:
- 5 or comprising SEQ ID NO:
- 261 or nucleic acid encoding one or more of SEQ ID NOs:
- 263-276, and a second isolated Bacillus amyloliquefaciens strain comprising SEQ ID NO:
- 10 or 11 or comprising SEQ ID NO:262 or nucleic acid encoding one or more of SEQ ID NOs:
- 277-284;
- wherein the metabolite comprises at least one of:
- histidine, N-acetylhistidine, phenyllactate (PLA), 1-carboxyethyltyrosine, 3-(4-hydroxyphenyl)lactate (HPLA), tryptophan, N-acetyltryptophan, anthranilate, indolelactate, isovalerylglycine, N-acetylisoleucine, N-acetylmethionine, urea, ornithine, spermidine, spermine, cysteinylglycine, pyruvate, sucrose, fumarate, deoxycarnitine, 2R,3R-dihydroxybutyrate, chiro-inositol, glycerophosphorylcholine (GPC), 5-aminoimidazole-4-carboxamide, xanthine, AMP, 2′-deoxyadenosine, dihydroorotate, UMP, uridine, CMP, cytidine, (3′-5′)-adenylyluridine, (3′-5′)-cytidylyladenosine, (3′-5′)-cytidylylcytidine, (3′-5′)-cytidylyluridine, (3′-5′)-guanylylcytidine, (3′-5′)-guanylyluridine, (3′-5′)-uridylylcytidine, (3′-5′)-uridylyluridine, (3′-5′)-uridylyladenosine, NAD+, oxalate (ethanedioate), maltol, 1-methylhistidine, N6,N6-dimethyllysine, S-methylcysteine, and 2-methylcitrate.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.